StockNews.AISignal intelligence
Omeros Corporation · NASDAQ · Healthcare
Browse public OMER signals with their source context and measured market impact. Open any signal for its permanent analysis page.
EMA CHMP cited trial design flaws and limited pediatric data for Yartemlea TA-TMA, limiting interpretability. Despite FDA approval and a US launch, EMA concerns could slow European uptake. CMS J-code set for July 1, 2026 and NTAP prospects support US reimbursement, but the EMA setback keeps OMER under pressure.
View signal analysisOMER prices its new drug at $36,000 per single-dose vial. The drug targets a life-threatening transplant complication for adults and children.
View signal analysisOMER's drug receives FDA approval for a dangerous transplant complication. This marks the first treatment approved specifically for this condition.
View signal analysisOmeros Corporation's stock rose over 150%. They secured a $2.1 billion deal with Novo Nordisk. The deal is for the MASP-3 inhibitor, zaltenibart. Investor confidence improved, alleviating bankruptcy fears. Continued operations now supported for Omeros Corporation.
View signal analysisH.C. Wainwright rates OMER as Buy with a $9 price target. Omeros approaches FDA decision on Narsoplimab expected September 25. Narsoplimab's approval could unlock $500-$1B commercial opportunity. Omeros is scaling back other initiatives to focus on Narsoplimab launch. Despite past losses, OMER shares are trending up by 3.58%.
View signal analysisOmeros established a Clinical Steering Committee for OncotoX program targeting AML. OncotoX shows high efficacy at low doses, exceeding current therapies. Therapeutic targets both AML blasts and refractory leukemia stem cells. Analyst maintains a Buy rating on OMER with a price target of $36. OMER stock recently surged by 13.2% to $6.64.
View signal analysis